A Rapid Health Technology Assessment of Xiyanping Injection in the Treatment of Respiratory System Diseases in Children

doi:10.14009/j.issn.1672-2124.2022.02.021

您当前的位置：

首页 >

文章列表页 >

A Rapid Health Technology Assessment of Xiyanping Injection in the Treatment of Respiratory System Diseases in Children

更新时间：2022-10-08

- A Rapid Health Technology Assessment of Xiyanping Injection in the Treatment of Respiratory System Diseases in Children
- Vol. 22, Issue 2, Pages: 208-212(2022)
- 作者机构：
  
  1. 北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院)
  2. 北京医院针灸按摩科国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院)
  3. 北京市宣武中医医院医疗保险办公室
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.02.021
  CLC： R956;R725.6
- Published：2022，
扫描看全文
A Rapid Health Technology Assessment of Xiyanping Injection in the Treatment of Respiratory System Diseases in Children. [J]. 22(2):208-212(2022)
DOI：

A Rapid Health Technology Assessment of Xiyanping Injection in the Treatment of Respiratory System Diseases in Children. [J]. 22(2):208-212(2022) DOI： 10.14009/j.issn.1672-2124.2022.02.021.

摘要

目的：快速评估喜炎平注射液治疗儿童呼吸系统疾病的有效性、安全性和经济性，为临床合理用药提供循证证据。方法：通过对万方数据库、中国知网、中国生物医学文献数据库、Embase、the Cochrane Library和PubMed等网站进行检索，纳入喜炎平注射液治疗儿童呼吸系统疾病的卫生技术评估(HTA)报告、系统评价/Meta分析和药物经济学研究，对纳入的资料进行分析汇总，并对文献及其方法学进行质量评价。结果：共纳入20篇文献，其中15篇为系统评价/Meta分析，5篇为药物经济学研究，未检索到HTA报告。分析结果显示，喜炎平注射液单独或联合西药治疗儿童呼吸系统疾病，在提高总有效率，缩短退热时间，缩短咳嗽、肺部啰音、气促、憋喘、咽痛和鼻塞流涕等临床症状缓解或消失时间，加快炎症吸收(胸部X线检查)

降低血清炎症因子水平，缩短住院时间和提高治愈率等方面均有一定作用。同时，喜炎平注射液的不良反应发生率显著低于对照组或与对照组相近。结论：喜炎平注射液治疗儿童呼吸系统疾病，可有效改善相关临床症状。未来可针对该药开展更深入的药物经济学研究和更为规范的临床观察、安全性评价，补充相关用药循证证据。

Abstract

OBJECTIVE: To rapidly evaluate the efficacy

safety and economical efficiency of Xiyanping injection in the treatment of respiratory system diseases in children

so as to provide evidence-based evidence for clinical rational drug use. METHODS: Wanfang Data

CNKI

CBM

Embase

the Cochrane Library and PubMed were retrieved to collect the health technology assessment（HTA） reports

systematic reviews/Meta-analysis and pharmacoeconomic studies related to Xiyangping injection in the treatment of respiratory system diseases in children. The included data were analyzed and summarized

and quality evaluation was performed on the literature and its methodology. RESULTS: A total of 20 articles were enrolled

15 were systematic reviews/Meta-analysis

5 were pharmacoeconomic studies

and no HTA reports were retrieved. Xiyanping injection alone or in combination with western medicine in the treatment of respiratory system diseases in children can improve the total effective rate

shorten the duration of fever

shorten the relief or disappearance time of cough

lung rales

shortness of breath

dyspnea

sore throat

nasal congestion and runny nose

accelerate the absorption of inflammation（chest X-ray examination）

reduce the serum inflammatory factor levels

shorten the length of stay

and improve the cure rate. Meanwhile

the incidence of adverse drug reactions of Xiyanping injection was significantly lower than or similar to the control group. CONCLUSIONS: Xiyanping jing injection has favorable efficacy in the treatment of respiratory system diseases in children. In the future

more in-depth pharmacoeconomic research and standardized clinical observations and safety evaluations can be carried out for Xiyanping injection

so as to provide the evidence-based evidence of related drug use.

关键词

喜炎平注射液儿童呼吸系统疾病卫生经济学快速卫生技术评估

Keywords

Xiyanping injectionChildrenRespiratory system diseaseHealth economicsRapid health technology assessment

references

查看原文

Views

113

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Rapid Health Technology Assessment of Shuxuening Injection in the Adjuvant Treatment of Ischemic Stroke

Rapid Health Technology Assessment of Xingnaojing Injection in the Treatment of Stroke

Rapid Health Technology Assessment of Shengmai Injection in the Treatment of Cardiac Failure

Rapid Health Technology Assessment on Shenfu Injection in the Treatment of Cardiac Failure

Rapid Health Technology Assessment of Roxadustat in the Treatment of Renal Anemia

Related Author

张碧华

邵晖

陈福安

杨莉萍

张碧华

母艳蕾

杨莉萍

张碧华

Related Institution

Audit Section, Beijing Xuanwu Traditional Chinese Medicine Hospital

Dept.of Neurology,Beijing Hospital/National Center for Gerontology/Institute of Geriatric Medicine, Chinese Academy of Medical Sciences/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application

Medical Insurance Office, Beijing Xuanwu Traditional Chinese Medicine Hospital

Dept.of Traditional Chinese Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences

首都医科大学附属北京朝阳医院药事部

⁰